Heron Therapeutics (HRTX) Misses Q1 EPS by 2c ; Offers Guidance

Heron Therapeutics (NASDAQ: HRTX) reported Q1 EPS of ($0.04), $0.02 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $34.7 million versus the consensus estimate of $39.28 million.

GUIDANCE:

Heron Therapeutics sees FY2026 revenue of $173-183 million, versus the consensus of $174.7 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.

You May Also Be Interested In

• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
• SPS Commerce hires Morgan Stanley, explores sale - Reuters
• Fastenal renews $835M credit facility, extends term to 2031